Microsaic optimistic about vaccine and drug technology first

Point of need mass spectrometry technology company Microsaic announced on Friday that in collaboration with the Center for Process Innovation (CPI), it had developed and demonstrated the first real-time monitoring process analysis (PAT) technology MS solution for in-line production of biotherapeutic drugs, such as cancer vaccines and treatments.

The AIM-listed company said that live data transmitted via “Internet of Things” (IoT) devices from the microengineering MS equipment would enable constant monitoring of production processes, to ensure high quality organic production.

He explained that the real-time alert system would allow rapid scale-up to large volumes, reduced supervision costs and accelerate cancer vaccines and treatments through emergency and standard regulatory clearance, and directly to patients.

“As part of the recent G7 directive to accelerate the production of vaccines and treatments to manage current and future pandemics, we are delighted to have taken this important step,” said Managing Director Glenn Tracey.

“In a short period of time, we have demonstrated and delivered an efficient automated production scale-up methodology to accelerate the time to market of drugs and vaccines, at a lower production cost and without manual human intervention, all maintaining high and consistent quality. “

Tracey said the company was unaware of another technology that could simultaneously analyze small and large molecules, in line production.

“We plan to interact with end-user manufacturing processes during the second half of this year, and we look forward to augmenting our system with other advanced artificial intelligence tools in our drive to stay ahead of the curve. of technology in Industry 4.0. time.”

At 1331 BST, shares of Microsaic Systems rose 15.56% to 0.26p.